Viewing data from:

ATRACURIUM BESYLATE

ANDA

ATRACURIUM BESYLATE | A074945 | WATSON PHARMACEUTICALS INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC

1 strength0 unique patents0 unique exclusivities

API Supply Chain5 active DMFs3 inactive

4 active API suppliers hold Drug Master Files for this ingredient.

FARMHISPANIA SAATRACURIUM BESYLATE USP

DMF 116071995

TAPI NL BVATRACURIUM BESYLATE

DMF 117421995

GLAND PHARMA LTDATRACURIUM BESYLATE USP

DMF 211892007

GLAND PHARMA LTDATRACURIUM BESYLATE USP [PROCESS-II]

DMF 296362015

SOLARA ACTIVE PHARMA SCIENCES LTDATRACURIUM BESYLATE USP

DMF 382382023

ABBOTT LABORATORIESInactiveATRACURIUM BESYLATE

DMF 111441994

QUIMICA ESTEROIDAL SA DE CVInactiveATRACURIUM BESYLATE

DMF 121201996

CF PHARMA LTDInactiveATRACURIUM BESYLATE

DMF 184442005

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jul 28, 1998	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 10MG/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Jul 28, 1998

No patent or exclusivity listings for this strength.